Zobrazeno 1 - 10
of 32
pro vyhledávání: '"Siddharth S. Kesharwani"'
Autor:
Hitesh Kumar, N. Vishal Gupta, Rupshee Jain, SubbaRao V. Madhunapantula, C. Saravana Babu, Siddharth S. Kesharwani, Surajit Dey, Vikas Jain
Publikováno v:
Journal of Advanced Research, Vol 54, Iss , Pp 271-292 (2023)
Background: Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive phenotype of breast cancer with associated chemoresistance. The development of chemo- or radioresistance could be attributed to diverse tumor microenvironments, overexpre
Externí odkaz:
https://doaj.org/article/ec7983a627684f118ffb5b2b40f5782e
Publikováno v:
Medicina, Vol 56, Iss 11, p 557 (2020)
About 40–70% of drug molecules in the clinical development pipeline suffer from one of either low aqueous solubility, poor absorption, or extremely low bioavailability. Approximately 75% of the world population relies on traditional therapies and t
Externí odkaz:
https://doaj.org/article/f1f4c589a8ce49adba7bcf152310f8e5
Autor:
Siddharth S. Kesharwani, Fady Ibrahim
Publikováno v:
AAPS PharmSciTech. 24
Autor:
Haritha V. Anod, Vikas Jain, Surajit Dey, Siddharth S. Kesharwani, Pallavi Chand, Hitesh Kumar, N. Vishal Gupta
Publikováno v:
Journal of Controlled Release. 326:628-647
Breast cancer (BC) is one of the most prevalent cancers in women. Triple-negative breast cancer (TNBC) in which the three major receptors i.e. estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), are
Publikováno v:
Medicina, Vol 56, Iss 557, p 557 (2020)
Medicina
Medicina
About 40–70% of drug molecules in the clinical development pipeline suffer from one of either low aqueous solubility, poor absorption, or extremely low bioavailability. Approximately 75% of the world population relies on traditional therapies and t
Autor:
Surajit Dey, Siddharth S. Kesharwani, Swagat Sharma, Vadikari Arun Kumar, Pooja Mallya, Vikas Jain
Publikováno v:
AAPS PharmSciTech. 21
Approximately 40% of compounds in clinical drug development suffer from solubility and bioavailability challenges. Evidence from literature demonstrates the growing interest to utilize flavonoids as potential compounds owing to their widespread thera
Autor:
Hemachand Tummala, Mrigendra Rajput, Siddharth S. Kesharwani, Pratik Muley, Sunny Kumar, Susmitha Narisetty
Publikováno v:
ACS Applied Materials & Interfaces. 10:27589-27602
Targeting dendritic cells (DCs), either ex vivo (Ex. Sipuleucel-T) or in vivo, for stimulating cellular immunity has been a leading approach for cancer vaccines. We have rationally engineered a nanoparticle (NP)-based delivery system for vaccines (In
Autor:
Hemachand Tummala, Rakesh Dachineni, G. Jayarama Bhat, Teresa Seefeldt, D. Ramesh Kumar, Ranjini Sankaranarayanan, Eduardo Callegari, Siddharth S. Kesharwani
Publikováno v:
International Journal of Oncology
Aspirin's potential as a drug continues to be evaluated for the prevention of colorectal cancer (CRC). Although multiple targets for aspirin and its metabolite, salicylic acid, have been identified, no unifying mechanism has been proposed to clearly
Autor:
Hemachand Tummala, Bhimanna Kuppast, Siddharth S. Kesharwani, Mohammed Ali Bakkari, Sunny Kumar
Publikováno v:
Journal of Controlled Release. 261:263-274
New and improved vaccines are needed against challenging diseases such as malaria, tuberculosis, Ebola, influenza, AIDS, and cancer. The majority of existing vaccine adjuvants lack the ability to significantly stimulate the cellular immune response,
Autor:
Ranjini Sankaranarayanan, Chaitanya K. Valiveti, D. Ramesh Kumar, Siddharth S. Kesharwani, Joy Scaria, Hemachand Tummala, Teresa Seefeldt, G. Jayarama Bhat, Severine Van Slambrouck
Publikováno v:
Cancers, Vol 11, Iss 3, p 427 (2019)
Cancers
Volume 11
Issue 3
Cancers
Volume 11
Issue 3
Flavonoids have emerged as promising compounds capable of preventing colorectal cancer (CRC) due to their anti-oxidant and anti-inflammatory properties. It is hypothesized that the metabolites of flavonoids are primarily responsible for the observed